Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hearing loss pill tested on police officers fizzles out

NCT ID NCT04774250

Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether the epilepsy drug zonisamide could prevent hearing damage in police officers after shooting range training. Only 3 people enrolled before the study was stopped early. The goal was to see if the drug could reduce hearing loss measured by hearing tests and ear sound emissions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zonisamide
What this could lead to
If it works, this could point toward a pill that protects hearing after sudden loud noise, like gunfire.
What could go wrong
The trial was terminated early with only 3 participants, so results are very limited. Zonisamide is an epilepsy drug and may cause side effects like dizziness or drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

3 people

The number who actually took part.

Started

Nov 2021

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Screening Inclusion Criteria: * Police officers who are scheduled for firearm training and/or certification on the range. * At least 18 years of age. * Air conduction thresholds are to be no worse than 25 dB HL from 0.5 kHz to 3 kHz, no worse than 30 dB HL at 4 kHz, and no worse than 45 dB HL at 6 and 8 kHz prior to shooting range exposure. * Ability to understand and willingness to sign an IRB approved written informed consent document. Enrollment Inclusion Criteria: * Observed audiometric TTS ≥ 10 dB HL at 2, 3, 4 and/or 6 kHz * Observed air-bone gap \< 10 dB HL at .5, 1, 2 and 4 kHz, with normal tympanometry Exclusion Criteria: * History of known sulfa allergy or hypersensitivity to carbonic anhydrase inhibitors. * History of moderate-to-severe kidney or liver disease. * Acute viral, bacterial, fungal or parasitic infection. * History of seizures. * Currently pregnant or breast-feeding. * Any current or history of otologic disorder. * History of ototoxic drug use. * Current use of strong/moderate 3A4 inhibitor/inducer and grapefruit juice. * For secondary outcomes, exclusion criteria is as follows: 1. DPOAE data will be used as a secondary outcome measure of TTS, and participants will be excluded if their DPOAE is absent at more than 3/7 frequencies. Criteria for a present response is any response that is \> 5 dB SPL above the noise floor and replicable within ±5 dB SPL. 2. ECochG: Participants will be excluded if the ECochG/ABR wave I response is absent. 3. WIN test: Participants with WIN scores greater than moderate difficulty or 14.9 dB SNR will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hearing loss, noise-induced are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

noise induced hearing loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hearing loss, noise-induced

Contacts and locations

Locations

  • University of Akron

    Akron, Ohio, 44325-3001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.